Head-to-head evidence
upadacitinib vs VC005
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atopic Dermatitis
Shared mechanism: JAK1 · full Atopic Dermatitis pipeline
upadacitinib · Rinvoq
Marketed by AbbVie
NCT03607422 · Phase 3 · completed
Participants were randomized and the trial was quadruple-blinded and placebo-controlled in 912 adolescents and adults. Both co-primary endpoints -- a 75% reduction in the validated Eczema Area and Severity Index (EASI75) and clearance or near-clearance on the validated Investigator Global Assessment -- were clearly met for both upadacitinib doses versus placebo at week 16 (p<0.001 for all comparisons).
Next expected readout: January 2027 · NCT06701331 (registry estimate)
VC005
Developed by Jiangsu Vcare Pharmatech and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: February 2027 · NCT07598383 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: upadacitinib's landscape · VC005's landscape